biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
DCS-273, monoclonal
form
buffered aqueous solution
mol wt
antigen 61 kDa
species reactivity
human
concentration
~2 mg/mL
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable, microarray: suitable, western blot: 2-4 μg/mL using whole extract of cultured 293T (human embryonal kidney) cells
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CHEK2(11200)
Immunogen
recombinant human Chk2.
Application
Suitable for immunohistochemistry (formalin-fixed, paraffin-embedded sections) and for immunoblotting at a concentration of 2 to 4 μg/mL using whole extract of cultured 293T cells.
Biochem/physiol Actions
The epitope recognized by the antibody resides within the FHA domain of the Chk2 molecule. This epitope is likely to be masked by protein-protein interactions in vivo.
The protein propagates signals from damaged or unreplicated DNA. The protein is expressed throughout the cell cycle. Upon activation it phosphorylates and inhibits CDC25C, which leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes, blocking cell cycle progression. It also regulates apoptosis through the phosphorylation of p53, a tumor suppressor protein. The protein regulates DNA repair through phosphorylation of BRCA2. Mutations in this gene have been linked to Li-Fraumeni syndrome, sarcomas, breast cancer, and brain tumors.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% BSA and 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
法规信息
新产品
此项目有
Zuzana Koledova et al.
Stem cells (Dayton, Ohio), 28(3), 450-461 (2010-01-28)
Cyclin-dependent kinase two (Cdk2) is the major regulator of the G1/S transition and the target of an activated G1 checkpoint in somatic cells. In the presence of DNA damage, Cdk2 kinase activity is abrogated by a deficiency of Cdc25A phosphatase
Yin Liu et al.
Human mutation, 32(9), 1000-1003 (2011-05-28)
The association between the CHEK2 and breast cancer risk in Chinese women is unknown. Here, we screened the full CHEK2 coding sequence in 118 Chinese familial breast cancer cases who are negative for mutations in BRCA1 and BRCA2, one recurrent
Igal Louria-Hayon et al.
The Journal of biological chemistry, 278(35), 33134-33141 (2003-06-18)
The p53 protein is kept labile under normal conditions. This regulation is governed largely by its major negative regulator, Mdm2. In response to stress however, p53 accumulates and becomes activated. For this to occur, the inhibitory effects of Mdm2 have
B B Zhou et al.
Nature, 408(6811), 433-439 (2000-12-02)
The inability to repair DNA damage properly in mammals leads to various disorders and enhanced rates of tumour development. Organisms respond to chromosomal insults by activating a complex damage response pathway. This pathway regulates known responses such as cell-cycle arrest
Vidar Staalesen et al.
Oncogene, 23(52), 8535-8544 (2004-09-14)
The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li-Fraumeni syndrome, and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| C9108-.2ML | 04061837867880 |
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持